5248042026-04-012026-06-305248042026-04-012026-06-30in-capmkt:OtherExpenses1Member5248042026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15248042026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25248042026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss35248042026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524804AUROPHARMANOTLISTEDINE406A01037AUROBINDO PHARMA LIMITEDMain BoardEquity2026-04-012027-03-312026-08-052026-07-27INRMillionsQuarterlyFirst quarterSingle segmentPharmaceutical products2026-08-0516:00:002026-08-0518:30:00Not applicable2026-04-012026-06-30UnauditedConsolidated91503500000264230000094145800000289440000009317800000-19923000001480150000010166000004868200000216219000007857770000015568100000-401800000151663000006100100000-12695000004830600000010335700000000-1540000010320300000-468700000985160000010325600000-53000009856900000-5300000575400000117.8617.860017.8617.86Notes: <br /> 1.The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <br /> 2.The above unaudited consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended. <br /> 3.The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on August 05, 2026. The results for the quarter ended June 30, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified opinion in respect of the limited review for the quarter ended June 30, 2026. <br /> 4.The Group operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment". <br /> 5.During the quarter ended June 30, 2026: <br /> i) The Company, incorporated a step down subsidiary, Arrow Pharma Production SAS, France through Agile Pharma B.V., Netherlands a wholly owned subsidiary of the Company w.e.f. May 21, 2026. <br /> ii) The Company invested Rs.5.2 million to acquire 26% stake in Swarnaakshu Solar Power Private Limited, India making it an associate company w.e.f. June 25, 2026. <br /> iii) The Company, incorporated a step down subsidiary, PT Auro Pharm Indonesia through PT Aurogen Pharma Indonesia, a wholly owned subsidiary of the Company w.e.f. July 01, 2026. <br /> <br /> 6.On July 30, 2025, the Company through it's wholly owned subsidiary, Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire 100% membership interest in Lannett Company LLC. <br /> <br /> On June 29, 2026 ('Acquisition date') the Company pursuant to above membership purchase agreement completed the acquisition of 100% membership interest in Lannett Company LLC along with its subsidiaries (Silarx Pharmaceuticals Inc, Kremers Urban Pharmaceuticals Inc and Cody Laboratories Inc) for a purchase consideration of Rs. 23,348.8 million (USD 247.1 million) upon satisfaction of customary closing conditions and receipt of the necessary regulatory approvals and has been consolidated with effect from that date. Hence, the results for the quarter ended June 30, 2026, are not comparable to the earlier periods presented. The transaction was accounted for in accordance with Ind AS 103 (Business Combinations), and the initial accounting has been provisionally determined. <br /> 7.The Board of Directors of the Parent Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement (“BTA”) to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis w.e.f April 01, 2026. <br /> <br /> Accordingly, the net assets of the business have been transferred at the consideration of Rs.1,432.1 million to Auropharm Limited. Since the transaction is with the wholly owned subsidiary of the Company, there is no impact on the unaudited consolidated financial statements. <br /> <br /> 8.Exceptional item: <br /> a) For the quarter ended June 30, 2026 includes acquisition and related costs of Rs.401.8 million (USD 4.3 million) in relation to the acquisition of 100% membership interest of Lannett Company LLC. <br /> <br /> b) During the year ended March 31, 2026, the Government of India consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Government is in the process of issuing related rules. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company assessed the implications of the New Labour Codes and recognized an incremental cost of Rs. 653.3 million during the year ended March 31, 2026. <br /> <br /> 9.The Board of Directors of Parent Company at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of Re. 1 each (representing 0.93% of the total number of equity shares of the parent company) for an aggregate value not exceeding Rs. 8,000.0 million (buyback size) (excluding transaction cost) at a maximum buyback price of Rs. 1,475 per equity share. Upon completion of the buyback, the parent company extinguished the equity shares in compliance with applicable rules and regulations. <br /> <br /> Consequently, the paid-up equity share capital has been reduced by Rs. 5.4 million. The aggregate amount paid for buyback is Rs. 8,065.3 million including related expenses. <br /> <br /> 10.Subsequent to the quarter end, on July 23, 2026, the Board of Directors of Apitoria Pharma Private Limited (a wholly owned subsidiary of the Company) approved the acquisition of an 80% ownership interest in the A1 Biochem Group, comprising A1 Biochem Labs (India) Private Limited, A1 Biochem Research (India) Private Limited and A1 Biochem Labs LLC, USA, at an enterprise value of USD 17.0 million on a debt-free and cash-free basis. <br /> The Company will invest USD 13.6 million for its 80% ownership interest in the A1 Biochem Group, subject to certain adjustments and conditions precedent, and the transaction is expected to be completed within 90-120 days. <br /> 11.During the current quarter, Aurobindo Pharma USA, Inc., a wholly owned subsidiary of the Company recorded net loss on derecognition of lease receivable of Rs.432.6 million (USD 4.5 million) which is included under the head “Other expenses”. <br /> 12.The figures for the quarter ended March 31, 2026, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and unaudited year to date published figures up to third quarter ended December 31, 2025, which were subject to limited review by the statutory auditors. <br /> Other expenses21621900000Re-measurement of defined employee benefit liability3600000Equity investment through other comprehensive income - net change in fair value.-81100000Income tax relating to items that will not be reclassified to profit or loss17500000-600000000Exchange differences on translating the financial statements of foreign operations.-408700000-4087000000-468700000